Navigation Links
Mount Sinai Technology Spinout RenalytixAI Completes Initial Public Offering, Raising $29 Million to Combat Kidney Disease
Date:11/13/2018

Mount Sinai Health System announced today that RenalytixAI PLC, a Mount Sinai exclusive licensee and development collaborator, had completed a public listing that valued the company at $85 million on the London Stock Exchange’s Alternative Investment Market. The public listing raised $29 million from a syndicate of health care institutional and industry investors, with participation from Mount Sinai.

RenalytixAI was formed to validate and commercialize artificial intelligence (AI)-enabled clinical diagnostic solutions for early detection of kidney disease and transplant management. The proceeds of this stock sale will be used in part to complete a multi-center clinical study anchored by Mount Sinai to validate KidneyIntelXTM for commercial launch in 2019. KidneyIntelX will focus on the early detection of kidney disease in patients who have type 2 diabetes or who are of African ancestry, two of the major population segments at risk for kidney disease throughout the United States.

Kidney disease is a public health crisis affecting an estimated 12 percent (or 120 million) of the U.S. and European populations, 90 percent of those affected are unaware they are at risk. The collaboration will leverage Mount Sinai assets, including world-renowned clinical expertise in nephrology, and access to the de-identified clinical data of 46,000 patient records in Mount Sinai’s BioMeTM BioBank repository and more than 3 million electronic health records in the Health System’s data warehouse.

In May 2018, Mount Sinai Health System and RenalytixAI finalized an initial collaboration for product development and intended translation to the clinic beginning in 2019.

RenalytixAI plans to develop a series of AI-enabled applications by mining a deep, unique pool of kidney disease-related data from diverse sources, including de-identified electronic health records, predictive blood-based biomarkers, and genomic information.

“RenalytixAI can now bring the clinical and financial resources together to drive advanced diagnostic development to combat the costs and management of kidney disease,” said James McCullough, Chief Executive Officer of RenalytixAI. “We are grateful to our investors and medical collaborators for this opportunity.”

“We are beginning with two products to determine who is at high risk for progression to kidney disease and dialysis, and what type of risk will be experienced by kidney transplant patients,” said Barbara Murphy, MD, Chair of the Samuel Bronfman Department of Medicine, Dean for Clinical Integration and Population Health at the Icahn School of Medicine at Mount Sinai, Board Member and Chair of the Scientific Advisory Board of RenalytixAI. “Kidney disease represents a major management issue from a population health perspective at Mount Sinai and other major medical centers, and these products will help us take on that challenge.”

“We’re thrilled to partner with RenalytixAI to develop much-needed prognostics and diagnostics that address the critical, unmet need of patients with high-risk of kidney disease,” said Erik Lium, PhD, Executive Vice President of Mount Sinai Innovation Partners. “Mount Sinai’s strengths in research, coupled with our robust clinical setting and valuable market perspective from RenalytixAI, will advance these solutions to the clinic.”

About Mount Sinai Innovation Partners

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, visit http://www.ip.mountsinai.org.

About RenalytixAI

RenalytixAI is a developer of AI-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.

RenalytixAI’s technology platform will draw from distinct sources of patient data, including systems containing extensive electronic health records, predictive blood-based biomarkers and other genomic information for analysis by high-performance, learning computer algorithms (machine learning).

About Kidney Disease

The International Society of Nephrology estimates that over 850 million people worldwide have some form of kidney disease, approximately twice that of diabetes (422 million) and 20 times more than cancer. By this estimate, kidney disease affects 10.4% of men and 11.8% of women worldwide.

In the US, chronic kidney disease affects over 40 million adults and kills more people than breast or prostate cancer. The co-occurrence of diabetes and cardiovascular disease multiplies a patient’s risk of death. Commonly referred to as a “silent disease” it is often asymptomatic until approximately 70% to 80% of kidney function has been lost. As a result, CKD is associated with significant morbidity, mortality and healthcare costs.

It is estimated that a third of adults in the US are at risk of kidney disease. This risk is greatest for those suffering from diabetes, high blood pressure, heart disease and obesity. Studies have also shown that ethnicity is a determining factor, with African Americans and Hispanic populations deemed most at risk. Americans of African ancestry are three times more likely to be afflicted by kidney disease than Caucasians, whilst those with Hispanic ancestry are almost 1.3 times more likely to be diagnosed with kidney failure compared to non-Hispanics.

Read the full story at https://www.prweb.com/releases/mount_sinai_technology_spinout_renalytixai_completes_initial_public_offering_raising_29_million_to_combat_kidney_disease/prweb15912811.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine technology :

1. David A. Feinberg Joins Mount Sinai Health System as Senior Vice President and Chief Marketing and Communications Officer
2. Mount Sinai and AllerGenis, LLC Announce Partnership to Bring Novel, Precision Diagnostics to Food Allergy Patients
3. Mount Sinai Experts Offer Tips on Prevention and Detection for Breast Cancer Awareness Month
4. Rocky Mountain Barber Company Launches North America’s First Free Razor Blade Program
5. Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018
6. DaVita Finalizes Acquisition of Mountain View Medical Group
7. Gradalis Announces Research Alliance with Mount Sinai
8. RFID Blood Monitoring Systems Market Gains From Mounting Emphasis on Efficient Patient Care, to Exceed US$174.2 Mn by 2019: Transparency Market Research
9. Pressure BioSciences Closes $550,000 First Tranche of $5 Million PIPE Over-Subscription Amount
10. Pressure BioSciences Exceeds $5 Million PIPE Goal and Opens $1.25 Million Over-Subscription Amount
11. Varian Imaging Components Business Highlights Claymount Products At RSNA Exhibit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2019)... ... February 19, 2019 , ... ... Contract (number MS11396) has been extended through January 31, 2021. This contract ... and TheraBond® product ranges to be available to Vizient members across the ...
(Date:2/19/2019)... ... February 19, 2019 , ... Brain ... The rapid growth of this sector is expected to reach $11.6 billion by ... the major leaders in this space. The company makes best in class, well-being ...
(Date:2/19/2019)... ... 2019 , ... ExceleraRx Corporation announced today that St. Luke’s Health System has ... member in the state of Idaho. , “We are very pleased to ... of ExceleraRx Corp. “We believe St. Luke’s commitment to expanding and leveraging its pharmacy ...
Breaking Medicine Technology:
(Date:2/22/2019)... , ... February 22, 2019 , ... ... regulated industries, today announced that Biscom Transit, Biscom’s cloud-based, secure email and file ... Awards in the category, Cybersecurity Product - Email Security. , This award recognizes ...
(Date:2/22/2019)... ... February 22, 2019 , ... ... to assist colleges and universities with their support service departments, which in return, ... and sustainable results, Soriant has a team of industry proven professionals with the ...
(Date:2/19/2019)... CHURCH, Va. (PRWEB) , ... February 19, 2019 ... ... Critical Thinking Skills and Innovative Techniques to Improve Inspections, **Presented by FDAnews and ... bird pricing for Conducting Advanced Root Cause Analysis CAPA Investigationsends on Feb. 26. ...
(Date:2/19/2019)... ... February 19, 2019 , ... In one ... pregnant and postpartum women, a team led by a Worcester Polytechnic Institute professor ... show increased depressive symptoms, greater weight gain during pregnancy, and weight retention after ...
(Date:2/19/2019)... ... , ... Pneumatic Vacuum Elevators, LLC has published a comprehensive ... make a house handicap accessible. , With this infographic , Pneumatic Vacuum ... accessible. To accurately educate consumers on handicap accessibility, the infographic covers how-to ...
Breaking Medicine News(10 mins):